Kennedy Capital Management LLC Cuts Stock Holdings in Encompass Health Corporation $EHC

Kennedy Capital Management LLC decreased its holdings in shares of Encompass Health Corporation (NYSE:EHC) by 13.4% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 61,063 shares of the company’s stock after selling 9,474 shares during the period. Kennedy Capital Management LLC owned 0.06% of Encompass Health worth $6,481,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in EHC. Royal Bank of Canada increased its position in Encompass Health by 21.5% during the 1st quarter. Royal Bank of Canada now owns 88,470 shares of the company’s stock valued at $8,960,000 after purchasing an additional 15,677 shares during the period. Millennium Management LLC increased its position in Encompass Health by 38.4% during the 1st quarter. Millennium Management LLC now owns 92,197 shares of the company’s stock valued at $9,338,000 after purchasing an additional 25,574 shares during the period. Caxton Associates LLP purchased a new position in Encompass Health during the 1st quarter valued at about $259,000. Walleye Capital LLC increased its position in Encompass Health by 667.6% during the 2nd quarter. Walleye Capital LLC now owns 6,522 shares of the company’s stock valued at $800,000 after purchasing an additional 7,671 shares during the period. Finally, Gamco Investors INC. ET AL purchased a new position in Encompass Health during the 2nd quarter valued at about $588,000. Hedge funds and other institutional investors own 97.25% of the company’s stock.

Encompass Health Stock Down 2.3%

EHC stock opened at $99.13 on Tuesday. The firm has a 50 day moving average of $104.35 and a 200 day moving average of $104.47. The stock has a market capitalization of $9.83 billion, a PE ratio of 16.55, a price-to-earnings-growth ratio of 2.21 and a beta of 0.72. The company has a quick ratio of 1.17, a current ratio of 1.17 and a debt-to-equity ratio of 0.76. Encompass Health Corporation has a 52 week low of $92.77 and a 52 week high of $127.99.

Encompass Health (NYSE:EHC) last released its earnings results on Thursday, April 30th. The company reported $1.60 EPS for the quarter, topping analysts’ consensus estimates of $1.51 by $0.09. The company had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.57 billion. Encompass Health had a net margin of 10.04% and a return on equity of 18.28%. Encompass Health’s revenue for the quarter was up 9.0% on a year-over-year basis. During the same period last year, the business earned $1.37 EPS. Encompass Health has set its FY 2026 guidance at 5.890-6.110 EPS. Sell-side analysts forecast that Encompass Health Corporation will post 5.97 earnings per share for the current year.

Encompass Health Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Wednesday, July 1st will be paid a $0.19 dividend. The ex-dividend date is Wednesday, July 1st. This represents a $0.76 dividend on an annualized basis and a yield of 0.8%. Encompass Health’s dividend payout ratio (DPR) is 12.69%.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. TD Cowen assumed coverage on shares of Encompass Health in a report on Thursday, May 28th. They issued a “buy” rating and a $125.00 price target on the stock. Weiss Ratings restated a “buy (b-)” rating on shares of Encompass Health in a report on Monday, June 8th. Leerink Partners set a $152.00 price target on shares of Encompass Health in a report on Friday, May 22nd. Barclays lowered their price target on shares of Encompass Health from $153.00 to $140.00 and set an “overweight” rating on the stock in a report on Tuesday, May 5th. Finally, Wall Street Zen upgraded shares of Encompass Health from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Encompass Health presently has a consensus rating of “Buy” and an average target price of $143.86.

Insider Buying and Selling

In related news, EVP Patrick William Tuer sold 682 shares of Encompass Health stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $104.56, for a total value of $71,309.92. Following the completion of the sale, the executive vice president directly owned 24,755 shares in the company, valued at $2,588,382.80. This trade represents a 2.68% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.80% of the stock is owned by company insiders.

Encompass Health Profile

Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.